Addus HomeCare stock
ADUSNASDAQAddus HomeCare Corporation, HealthcareISIN US0067391062
71Score 71 out of 100, Strong
Price and trend
88 / 100
Price history
+8.8% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 3.3% below its 52-week high. Largest decline in 17 years: 70% (January 2010 to November 2010).
Chart figures for advanced users
- SMA 50$118.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$107.12
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$88.49
- The lowest closing price of the last twelve months.
- Resistance$127.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Addus HomeCare Corporation belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $2.31B, is number 28 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.42B (up 23.2% year on year) and earnings of $95.91M (up 30.3%).
- For fiscal 2026, analysts expect on average revenue of $1.52B (up 7.1%) and adjusted earnings per share of $7.05 (up 13%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 111 of 714 in Healthcare, median 53.
- The P/E is 20.7 (Medical (Care Facilities) median 19.4, own median of recent years 33.1).
- Our model puts fair value at $130.91, with the price 4% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 19.6% a year since 2020.Growth 78
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
- More cash than debtCash $98.48M, financial debt $67.33M.Stability 86
Weaknesses
- DilutionShare count up 17% since 2020.Capital allocation 36
Its standout strengths are technical analysis and stability, while capital allocation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $100.70 and expensive above $187.01 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $146.07 (cash-flow model) and $115.75 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $118.95, at 7.8% it would be $148.84.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.5% on the twelve months before. Revenue has grown solidly since 2007, at about 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 32%, operating 10%, net 7%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Feb 2027in 101 days
- Last reported
- 3 Nov 2026EPS reported $1.83 (expected $1.79)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $7.05+0.1%
- Revenue
- $1.52B0.0%
- Earnings per share
- $7.540.0%
- Revenue
- $1.62B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.3%No numerical guidance: the final fiscal 2027 hospice rate is about 30 basis points below the prior year, and gross margin should follow the usual annual pattern.
“On July 30, CMS published the final fiscal 2027 hospice rate, which will be effective on October 1, 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $16.35M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Allison R DirkSale
9 Nov 2026, Chairman and CEO
- Shares
- 98,958
- Price
- $123.27
- Value
- $12.2M
- Wattenbarger Michael D.Sale
6 Nov 2026, EVP, Chief Information Officer
- Shares
- 7,141
- Price
- $124.67
- Value
- $890,278
- Raines MonicaSale
6 Nov 2026, EVP, CCO and Quality Officer
- Shares
- 2,062
- Price
- $124.74
- Value
- $257,214
Show 6 more
- Tucker David W.Sale
6 Nov 2026, EVP, Chief Strategy Officer
- Shares
- 14,850
- Price
- $124.75
- Value
- $1.85M
- Poff BrianSale
6 Nov 2026, EVP, Chief Financial Officer
- Shares
- 6,644
- Price
- $124.72
- Value
- $828,642
- Blessing Cliff DonaldSale
6 Nov 2026, EVP, Chief Development Officer
- Shares
- 2,000
- Price
- $124.18
- Value
- $248,360
- Dixon Heather BrianneSale
22 Jun 2026, President and Chief Operating
- Shares
- 288
- Price
- $93.77
- Value
- $27,006
- Lopez EstebanSale
21 May 2026, Board
- Shares
- 250
- Price
- $93.00
- Value
- $23,250
- Lopez EstebanSale
19 May 2026, Board
- Shares
- 250
- Price
- $93.00
- Value
- $23,250
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Addus HomeCare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Guardian Pharmacy ServicesGRDN $3.16B77
- Aveanna Healthcare HoldingsAVAH $2.86B63
- Ardent HealthARDT $2.56B60
- Pediatrix Medical GroupMD $2.46B70
- Brookdale Senior LivingBKD $2.2B24
- Agilon HealthAGL $1.93B48
- EmeisEMEIS.PA $1.92B41
- AttendoATT.ST $1.87B65
ETFs that hold Addus HomeCare
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.20% | 0.40% | €807M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.17% | 0.30% | €185.82M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.13% | 0.30% | €2.28B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.08% | 0.30% | €2.17B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.04% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.